Purple Biotech Ltd. filed a March 2026 corporate presentation as Exhibit 99.1, highlighting the CAPTN-3 platform with lead tri-specific antibody IM1240 entering preclinical toxicology studies in 2026, IND submission, and Phase 1 initiation in 2027, alongside clinical-stage assets CM24 and NT219 available for partnering.
Key takeaways
Cash $9.5M as of December 31, 2025 with runway into H1 2027 covering IM1240 tox, IND, and Phase 1 initiation